MedTrace Logo

Effects of Pycnogenol on Cardiac Fibrosis and Diastolic Dysfunction in Aged Hypertensive Subjects

NCT00952627 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-12-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether Pycnogenol, a natural pine bark extract, is effective in modifying the age-dependent process of cardiac fibrosis and diastolic function in aged hypertensive subjects.

Conditions

  • Cardiac Fibrosis
  • Diastolic Dysfunction

Interventions

DIETARY_SUPPLEMENT

Pycnogenol

50 mg tablet, 200 mg/day, 4 tablets/day

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Horphag Research

    collaborator UNKNOWN

  • University of Arizona

    lead OTHER

Principal Investigators

  • Ronald R Watson, PhD · University of Arizona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952627 on ClinicalTrials.gov